Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality

Proteome Science

Volumn 12, Issue 1, 2014, Pages

  Shipitsin, Michail ^a   Small, Clayton ^a   Giladi, Eldar ^a,d   Siddiqui, Summar ^a,e   Choudhury, Sibgat ^a   Hussain, Sadiq ^a   Huang, Yi E ^a   Chang, Hua ^a   Rimm, David L ^b   Berman, David M ^c   Nifong, Thomas P ^a   Blume Jensen, Peter ^a,f  

^a Metamark Genetics Inc   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c QUEEN S UNIVERSITY   (Canada)

^d Atreca Inc   (United States)

^e MODERNA THERAPEUTICS   (United States)

^f XTuit Pharmaceuticals   (United States)

Author keywords

Biomarkers; Object recognition; Prostate cancer; Protein activity states; Quantitative multiplex immunofluorescence

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOSERINE; PHOSPHOSERINE S6; PHOSPHOTHREONINE; PPRAS40 PROTEIN; SMAD4 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOMATION; CANCER MORPHOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME ACTIVITY; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOFLUORESCENCE; LETHALITY; MAJOR CLINICAL STUDY; MALE; MOLECULAR IMAGING; MULTIPLEX IMMUNOFLUORESCENCE IN SITU IMAGING; PHENOTYPE; PREDICTIVE VALUE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; TISSUE SECTION;

EID: 84904079079     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-12-40     Document Type: Article

References (33)

1. Hudson TJ. Genome variation and personalized cancer medicine. J Intern Med 2013, 274:440-450.
2. Liehr T, Weise A, Hamid AB, Fan X, Klein E, Aust N, Othman MA, Mrasek K, Kosyakova N. Multicolor FISH methods in current clinical diagnostics. Expert Rev Mol Diagn 2013, 13:251-255.
3. Cheng S, Koch WH, Wu L. Co-development of a companion diagnostic for targeted cancer therapy. N Biotechnol 2012, 29:682-688.
4. Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2012, 9:520-528.
5. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
6. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, Moller H, Scardino P, Warren JD, Park J, Younus A, Flake DD, Wagner S, Gutin A, Lanchbury JS, Stone S, . Transatlantic Prostate Group Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011, 12:245-255. Transatlantic Prostate Group.
7. Kaklamani V. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX. Expert Rev Mol Diagn 2006, 6:803-809.
8. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, DePinho RA. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011, 470:269-273.
9. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999, 59:4291-4296.
10. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, Squire JA. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007, 97:678-685.
11. Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, Camacho N, Merson S, Brewer D, Cooper CS, Clark J, Berney DM, Møller H, Scardino P, Sangale Z, . Transatlantic Prostate Group Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer 2013, 108:2582-2589. Transatlantic Prostate Group.
12. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012, 13:283-296.
13. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
14. Mansfield JR, Hoyt C, Levenson RM. Visualization of microscopy-based spectral imaging data from multi-label tissue sections. Curr Protoc Mol Biol 2008, 14:14. Unit 14 19.
15. Kristiansen G. Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology 2012, 60:125-141.
16. Brimo F, Epstein JI. Immunohistochemical pitfalls in prostate pathology. Hum Pathol 2012, 43:313-324.
17. Portier BP, Wang Z, Downs-Kelly E, Rowe JJ, Patil D, Lanigan C, Budd GT, Hicks DG, Rimm DL, Tubbs RR. Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry. Mod Pathol 2013, 26:1-9.
18. Hicks DG, Boyce BF. The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research. Biotech Histochem 2012, 87:14-17.
19. Holzer TR, Fulford AD, Arkins AM, Grondin JM, Mundy CW, Nasir A, Schade AE. Ischemic time impacts biological integrity of phospho-proteins in PI3K/Akt, Erk/MAPK, and p38 MAPK signaling networks. Anticancer Res 2011, 31:2073-2081.
20. Hunter T. Signaling-2000 and beyond. Cell 2000, 100:113-127.
21. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
22. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
23. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P, Paweletz CP. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med 2010, 2:43-55.
24. Yang JY, Hung MC. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res 2009, 15:752-757.
25. Wang H, Zhang Q, Wen Q, Zheng Y, Lazarovici P, Jiang H, Lin J, Zheng W. Proline-rich Akt substrate of 40 kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. Cell Signal 2012, 24:17-24.
26. Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, Roth RA. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem 2003, 278:10189-10194.
27. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002, 8:1323-1327.
28. Donovan MJ, Hamann S, Clayton M, Khan FM, Sapir M, Bayer-Zubek V, Fernandez G, Mesa-Tejada R, Teverovskiy M, Reuter VE, Scardino PT, Cordon-Cardo C. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol 2008, 26:3923-3929.
29. Teverovskiy M, Vengrenyuk Y, Tabesh A, Sapir M, Fogarasi S, Ho-Yuen P, Khan FM, Hamann S, Capodieci P, Clayton M, Kim R, Fernandez G, Mesa-Tejada R, Donovan MJ. Automated localization and quantification of protein multiplexes via multispectral fluorescence imaging. Biomedical Imaging: From Nano to Macro, 2008 ISBI 2008 5th IEEE International Symposium on; 14-17 May 2008 2008, 300-303.
30. Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005, 2005(29):1228-1242.
31. Yan P, Seelentag W, Bachmann A, Bosman FT. An agarose matrix facilitates sectioning of tissue microarray blocks. J Histochem Cytochem 2007, 55:21-24.
32. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012, 9:671-675.
33. Linkert M, Rueden CT, Allan C, Burel JM, Moore W, Patterson A, Loranger B, Moore J, Neves C, Macdonald D, Tarkowska A, Sticco C, Hill E, Rossner M, Eliceiri KW, Swedlow JR. Metadata matters: access to image data in the real world. J Cell Biol 2010, 189:777-782.